Anaplastic thyroid carcinoma: review of treatment protocols

被引：93

作者：

Tiedje, Vera ^{[1
]}

Stuschke, Martin ^{[2
]}

Weber, Frank ^{[3
]}

Dralle, Henning ^{[3
]}

Moss, Laura ^{[4
]}

Fuehrer, Dagmar ^{[1
]}

机构：

[1] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Endocrine Tumour Ctr,Dept Endocrinol Diabetol & M, Essen, Germany

[2] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Radiotherapy, Essen, Germany

[3] Univ Duisburg Essen, Univ Hosp Essen, Sect Endocrine Surg, Dept Gen Visceral & Transplantat Surg, Essen, Germany

[4] Velindre Canc Ctr, Cardiff, S Glam, Wales

来源：

关键词：

anaplastic thyroid carcinoma; treatment protocol; radiotherapy; targeted therapy; ASSOCIATION GUIDELINES; SINGLE-INSTITUTION; CANCER; SURVIVAL; CHEMOTHERAPY; MANAGEMENT; BRAF; FOSBRETABULIN; VEMURAFENIB; THERAPY;

D O I：

10.1530/ERC-17-0435

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anaplastic thyroid carcinoma (ATC) is an orphan disease and in most patients fatal. So far no established treatment is available that prolongs survival. Several large retrospective studies have identified negative prognostic markers, analyzed efficacy of multimodal approaches such as radiotherapy with and without concurrent chemotherapy and chemotherapy protocols. Recently, single case reports have suggested some effectiveness of newer therapies targeting single somatic alterations in ATC. Overall, the conclusions that can be drawn from published retrospective studies and the scarce prospective approaches is that new treatment protocols should be developed including surgery, radiotherapy, chemotherapy and targeted therapy approaches and combinational therapy with immunotherapies. These protocols then need to be evaluated prospectively to improve ATC patients' outcome in routine care.

引用

页码：R153 / R161

页数：9

共 47 条

[1] Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer [J].

Agarwal, Rishi ;

Wang, Jiang ;

Wilson, Keith ;

Barrett, William ;

Morris, John C. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (10) :1203-1207

[2]

Baek SK, 2016, HEAD NECK-J SCI SPEC, V39, P133

[3] A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer [J].

Bible, Keith C. ;

Suman, Vera J. ;

Menefee, Michael E. ;

Smallridge, Robert C. ;

Molina, Julian R. ;

Maples, William J. ;

Karlin, Nina J. ;

Traynor, Anne M. ;

Kumar, Priya ;

Goh, Boon Cher ;

Lim, Wan-Teck ;

Bossou, Ayoko R. ;

Isham, Crescent R. ;

Webster, Kevin P. ;

Kukla, Andrea K. ;

Bieber, Carolyn ;

Burton, Jill K. ;

Harris, Pamela ;

Erlichman, Charles .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (09) :3179-3184

[4] Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer [J].

Brauner, Eran ;

Gunda, Viswanath ;

Vanden Borre, Pierre ;

Zurakowski, David ;

Kim, Yon Seon ;

Dennett, Kate Virginia ;

Amin, Salma ;

Freeman, Gordon James ;

Parangi, Sareh .

ONCOTARGET, 2016, 7 (13) :17194-17211

[5] Early Surgery and Survival of Patients with Anaplastic Thyroid Carcinoma: Analysis of a Case Series Referred to a Single Institution Between 1999 and 2012 [J].

Brignardello, Enrico ;

Palestini, Nicola ;

Felicetti, Francesco ;

Castiglione, Anna ;

Piovesan, Alessandro ;

Gallo, Marco ;

Freddi, Milena ;

Ricardi, Umberto ;

Gasparri, Guido ;

Ciccone, Giovannino ;

Arvat, Emanuela ;

Boccuzzi, Giuseppe .

THYROID, 2014, 24 (11) :1600-1606

[6] Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer [J].

Cabanillas, Maria E. ;

Williams, Michelle D. ;

Gunn, G. Brandon ;

Weitzman, Steven P. ;

Burke, Laura ;

Busaidy, Naifa L. ;

Ying, Anita K. ;

Yiin, Yeh Hung ;

William, William N. ;

Lu, Charles ;

Lai, Stephen Y. .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2017, 39 (07) :1291-1295

[7] Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors [J].

Danilova, Ludmila ;

Wang, Hao ;

Sunshine, Joel ;

Kaunitz, Genevieve J. ;

Cottrell, Tricia R. ;

Xu, Haiying ;

Esandrio, Jessica ;

Anders, Robert A. ;

Cope, Leslie ;

Pardoll, Drew M. ;

Drake, Charles G. ;

Taube, Janis M. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (48) :E7769-E7777

[8] Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy [J].

De Crevoisier, R ;

Baudin, E ;

Bachelot, A ;

Leboulleux, S ;

Travagli, JP ;

Caillou, B ;

Schlumberger, M .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (04) :1137-1143

[9] German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors [J].

Dralle, Henning ;

Musholt, Thomas J. ;

Schabram, Jochen ;

Steinmueller, Thomas ;

Frilling, Andreja ;

Simon, Dietmar ;

Goretzki, Peter E. ;

Niederle, Bruno ;

Scheuba, Christian ;

Clerici, Thomas ;

Hermann, Michael ;

Kussmann, Jochen ;

Lorenz, Kerstin ;

Nies, Christoph ;

Schabram, Peter ;

Trupka, Arnold ;

Zielke, Andreas ;

Karges, Wolfram ;

Luster, Markus ;

Schmid, Kurt W. ;

Vordermark, Dirk ;

Schmoll, Hans-Joachim ;

Muehlenberg, Reinhard ;

Schober, Otmar ;

Rimmele, Harald ;

Machens, Andreas .

LANGENBECKS ARCHIVES OF SURGERY, 2013, 398 (03) :347-375

[10] Long-term results of radiotherapy in anaplastic thyroid cancer [J].

Dumke, Anne-Katrin ;

Pelz, Tanja ;

Vordermark, Dirk .

RADIATION ONCOLOGY, 2014, 9

← 1 2 3 4 5 →